INTRODUCTION
Thrombophilia is a suspected risk factor for placenta-mediated pregnancy complications that include recurrent pregnancy loss, intrauterine growth restriction, stillbirth, placental abruption and preeclampsia 1, 2 . These complications affect a significant proportion of all pregnancies and are a major cause of maternal and fetal morbidity and mortality [3] [4] [5] . Treatment of these disorders with low molecular weight heparin (LMWH) has shown mixed outcomes, with recent meta-analyses suggesting absence of significant benefit [6] [7] [8] . Humans and rodents form a hemochorial placenta where extraembryonic trophoblast cells replace maternal vascular endothelium. The interfaces of maternal blood and trophoblast cells are potential sites of pathologic coagulation 9 . At these sites, maternal platelets could participate in thrombosis and/or engage inflammatory mechanisms causing pregnancy complications. Given the low 50% effective concentration (EC 50 ) of thrombin-mediated platelet activation, it is unclear if treatment with LMWH reduces local thrombin generation to levels below those needed for platelet activation. In this work, we first used murine models to rigorously examine whether maternal platelet activation plays a key role in placental failure due to fetal thrombophilia. We next investigated if maternal thrombophilia is associated with pregnancy complications and the potential for anti-platelet and anti-thrombotic therapy.
The endothelial protein C receptor (EPCR) is an anticoagulant protein highly expressed on trophoblast cells 9, 10 . EPCR binds to protein C (PC) and facilitates its activation by the thrombin-thrombomodulin complex. Activated PC (aPC) inhibits excessive thrombin generation by limited proteolytic cleavage and inactivation of coagulation factors Va and VIIIa. EPCR gene polymorphisms and presence of EPCR autoantibodies in the mother are associated with recurrent miscarriages and unexplained pregnancy loss [11] [12] [13] [14] . In mice, absence of EPCR in the fetus results Castillo in placental thrombosis and mid-gestational fetal death 15 . Intrauterine death of EPCR-deficient mice is prevented by concomitant reduction in tissue factor (TF) or by maintaining EPCR expression on trophoblast cells. Yet, treatment of pregnant dams with LMWH prolongs survival of only a small fraction of EPCR-deficient embryos 16 . Mice carrying a variant of EPCR with impaired ability to bind PC/aPC are viable without reported placental thrombosis and intrauterine death 17 . Though most well studied for their role in anticoagulation, new roles of aPC and EPCR in stem cell function [18] [19] [20] [21] [22] , inflammation [23] [24] [25] and immunity 26, 27 have recently emerged. Thus, the mechanism of placental failure and whether it is primarily mediated by the loss of anticoagulation by EPCR remains unclear.
RESULTS

Thrombin activation of maternal platelets kills EPCR-deficient embryos:
Platelet activation is an integral part of thrombosis. Maternal platelets surround the implantation site in close proximity to extraembryonic trophoblast cells in murine ( Figure 1 ) and human placenta 28 . Their activation could contribute to placental failure of EPCR-deficient embryos. Analogous to Protease Activated Receptor (PAR) 1 and PAR4 on human platelets, murine platelets express dual thrombin receptors Par3 and Par4. Par3 promotes cleavage and activation of Par4 at low thrombin concentration. In the absence of Par3, platelets continue to be activated via Par4 but the EC 50 of platelet activation by thrombin increases from 0.10 ± 0.08 nM to 1.5 ± 0.7 nM 29 . Murine platelets lacking Par4 are unresponsive to thrombin 30 . We conducted genetic studies to determine if activation of maternal platelets via thrombin receptor Par3 and Par4 plays a critical role in placental failure of EPCR-deficient mice. Mice lacking EPCR die in utero before 11.5 days post coitum (dpc) in pregnancies from EPCR +/intercrosses ( 15 ). We analyzed pregnancies of Par4 -/-EPCR +/dams sired by EPCR +/males at 11.5 dpc (Table 1, row 3) . Absence of Par4 in the mother allowed embryonic development of EPCR -/embryos (Table 1, compare rows 1 & 3, P<<0 .001,  2 test of independence). These were normal in appearance and showed placental development comparable to littermate EPCR +/+ controls (Figure 2 A-F). In this genetic experiment, the mother lacked Par4 and the fetuses (and their extraembryonic tissues) were heterozygous for Par4. Par4 is expressed on a variety of cell types that include trophoblast cells 9 . To confirm that the observed effects reflect maternal Par4 deficiency rather than fetal haploinsufficiency, we performed reverse genetic crosses where Par4 -/-EPCR +/males sired pregnancies of EPCR +/dams. Absence of Par4 in the father alone did not protect EPCR -/embryos from mid-gestational death; no live Par4 +/-EPCR -/embryos were found at 11.5 dpc in these pregnancies ( Aspirin reduces platelet aggregation by inhibiting Cox-1 and Cox-2 enzymes and has been tested for its ability to improve outcomes in human pregnancy. In EPCR +/intercrosses, aspirin treatment of pregnant dams prolonged the survival of EPCR-deficient embryos but did not restore normal placental development (Supplementary note 1 and Figure S1 A-E). In contrast, depletion of maternal platelets restored placental development and allowed survival of EPCR-deficient embryos (Supplementary note 2 and Figure S1 F-I). Upon activation by thrombin, platelets convert integrin αIIbβ3 to its high affinity state. Integrin αIIbβ3 mediates binding to fibrinogen and von Willebrand factor and plays a key role in platelet aggregation.
Inhibitors of αIIbβ3 that block this common pathway of platelet adhesion and aggregation have been used in the management of acute coronary syndromes 31 . We tested the role of integrin αIIbβ3 in placental failure of EPCR-deficient mice. Genetic inactivation of αIIb in the mother fully protected EPCR -/embryos from mid-gestational death ( observed, 25% expected, P=0.276,  2 GOF). In each of these crosses, 100% of EPCR -/mice that survived past the first week of birth exhibited normal life spans (> 1 year of age). Thus, EPCRdeficient pups are vulnerable in the perinatal period, and many died within the first few days of birth. We examined EPCR -/neonates from each of these genetic crosses but did not discover any obvious potential cause of death. However, we observed that EPCR-deficient embryos in pregnancies of Par3 -/-EPCR +/dams were significantly smaller than their littermates at 18.5 dpc.
The reduction in size was also observed for their corresponding placentae. A similar reduction was noted in placental sizes for EPCR-deficient concepti in pregnancies of Par4 -/-EPCR +/and αIIb -/-EPCR +/dams and in sizes of EPCR-deficient embryos in pregnancies of αIIb -/-EPCR +/dams ( Figure 3 A-J). Histological examination of late gestation placentae in each of these genetic crosses strikingly revealed thrombi in the junctional zone of EPCR -/placentae. EPCR is highly expressed in the spongiotrophoblast cells of the junctional zone in normal mouse placentae. The junctional zone is traversed by trophoblast lined venous sinuses that drain maternal blood from the labyrinth to decidua basalis 32 . Frequent thrombi were observed in these channels in EPCR -/but not in littermate EPCR +/+ placentae (Figure 3 K-T). Calcified and infarcted regions were also frequently observed in the placental labyrinth, but these did not correlate with any specific genotype. EPCR -/mice continued to exhibit neonatal lethality even when both maternal and fetal genes for Par4, Par3 or αIIb were inactivated (Table 1, These data show a remarkable association between placental thrombosis (due to EPCR deficiency on trophoblast cells) and the high neonatal lethality of EPCR -/mice. Neonatal lethality is not observed when EPCR expression is maintained on trophoblast cells but removed from the embryo. Inactivation of maternal Par4, Par3 or αIIb each improved survival, but did not completely overcome placental thrombosis and associated neonatal death.
Inactivation of coagulation factor VIII protects EPCR-deficient embryos:
Daily injections of 20μg/g of LMWH was reported to prolong survival of a small fraction of EPCR-deficient mice; 2 out of 48 pups born from heterozygous intercrosses were found to be EPCR -/-(4.2% observed, 25% expected) 16 . In our laboratory, continuous delivery of LMWH through subcutaneously implanted osmotic pumps also resulted in marked anticoagulation but did not restore normal placental development (Supplementary note 3 and Figure S2 ). To rigorously test the role of excess thrombin generation in fetal demise, we conducted breeding experiments using mice in which FVIII was genetically inactivated. FVIIIa supports the propagation of thrombin generation via intrinsic tenase (FVIIIa-FIXa) formation. It is one of the targets of inactivation by aPC. We analyzed pregnancies of FVIII -/-EPCR +/dams sired by FVIII -/y EPCR +/males. (Note that FVIII is an X-linked gene with a single copy in males.) EPCR -/embryos were present at expected Mendelian frequency at 18.5 dpc ( generation by inactivating FVIII was also effective in preventing early death of EPCR-deficient embryos, but insufficient in preventing late placental thrombosis and high neonatal lethality.
Nonetheless, FVIII inactivation significantly improved survival of EPCR-deficient embryos ( 
Platelets cause placental failure independent of thrombin generation:
Par4 activated platelets enhance thrombin generation. Given the similar protective effect of FVIII and Par4 inhibition, we asked whether protection from early placental failure seen in the absence of platelet receptors Par4, Par3 or αIIb might reflect their reduced ability to participate in thrombin generation. To address this question, we performed thrombin generation assays with platelet rich plasma (PRP) from Par4 -/-, Par3 -/or αIIb -/mice using recombinant TF as a trigger ( Figure 4 ). As expected, Par4 -/-PRP showed reduced thrombin peak height (45.5 ± 20 nmol Par4 - were increased in αIIb -/-PRP compared to wild type controls (peak height 289.5 ± 42.6 nmol αIIb -/-; P << 0.0001 and total thrombin generation 3304.9 ± 412.5 nmol αIIb -/-; P = 0.0003).
Thus, the benefit observed with inactivation of platelet Par4 or Par3 is unlikely to be due to reduced platelet participation in thrombin generation, but rather involves other pathogenic events downstream of platelet activation.
Maternal EPCR deficiency causes severe pregnancy complications:
Adult EPCR-deficient mice generated by maintaining placental expression (EPCR δ/δ ) exhibit plasma markers of thrombophilia without overt thrombosis 16 . They can serve as a useful model to investigate whether maternal thrombophilia predisposes pregnancies to placentamediated complications. In the course of our studies, we discovered severe pregnancy complications in pregnancies of FVIII -/-EPCR -/females sired by wild type males. Two of the four pregnancies that we analyzed exhibited mid-gestational vaginal bleeding. One female died towards term gestation (19.5 dpc) and three were moribund. Surgical evaluation revealed retroplacental bleeding, blanched organs and undelivered live pups. It was unclear if this was a phenomenon of concomitant EPCR and FVIII deficiencies. To address this further, we evaluated pregnancy outcome of EPCR-deficient females that were generated by maintaining EPCR expression in the placenta (EPCR δ/δ ). We analyzed 18 pregnancies of 12 dams sired by wild type males. Of these, 8 pregnancies (44%) resulted in maternal death or moribund mother requiring euthanasia. One maternal death occurred on 13.5 dpc and two on 15.5 dpc. In the remaining 5 cases the mother was moribund past the expected delivery date; 4 of these were associated with dead or live pups that had not been delivered. In addition, 2/18 pregnancies resulted in stillborn 
DISCUSSION
In this work, we used genetic strategies to first examine whether thrombin generation and maternal platelet activation play key roles in placental failure due to fetal thrombophilia. We demonstrate that thrombin-mediated activation of maternal platelets causes the early placental Page Par3, αIIb or FVIII in the mother, father or both parents. showed thickened maternal decidua and giant cells, but no labyrinth was elaborated ( Figure S1 A-E). Thus, aspirin treatment prolonged survival of a small fraction of EPCR-deficient embryos but did not restore normal placental development.
Note 2
We examined whether depletion of platelets allows development of EPCR -/placentae past 10.5 dpc. Plugged females from EPCR +/intercrosses were injected at 7.5 dpc with platelet depleting antibodies directed against GP1b. Treatment results in transient thrombocytopenia in the pregnant dam that lasts for 4 days after treatment (Figure S1 J & K). Analysis of two pregnancies at 11.5 dpc showed 2/16 embryos to be EPCR -/-. In another treated pregnancy analyzed at 15.5 dpc, 1 of 6 embryos was EPCR -/-. In all three pregnancies, EPCR-deficient embryos and placentae were normal in size, appearance, and histological features (Figure S1 F-I). Thus, treatment of the mother with platelet depleting antibodies restored placental development and improved survival of EPCR-deficient embryos.
Note 3
To be able to examine if LMWH restores development of EPCR -/placentae, we repeated the previously published experiment where pregnant dams from EPCR +/intercrosses were treated with LMWH 16 . To achieve continuous anticoagulation, we implanted pregnant females with subcutaneous osmotic pumps that delivered LMWH at 25μg/hour from 5.5 dpc till the time that pregnancies were analyzed. Treatment resulted in 3 EPCR -/out of 19 live embryos analyzed at 11.5 dpc. All three embryos were smaller, and one was severely growth restricted. All three placentae showed marked reduction in placental labyrinth formation ( Figure S2 ). Treatment resulted in significant anticoagulation measured as 0.3 to 0.5 IU of FXa inhibitory activity per mL of maternal plasma. Thus, normal placental development could not be restored even with continuous anticoagulation with LMWH.
MATERIALS AND METHODS
Mice
Par4 (MMRRC stock number: 15231), Par3 (MMRRC stock number: 15232), αIIb, FVIII, EPCR loxP and Meox2Cre (Jackson laboratory, stock number 003755) mice have been previously described 30, 39-42, 16, 43 
Histology and Immunohistochemistry
For most experiments, tissues were fixed in zinc formalin for 72 hours and transferred to 70% alcohol for future processing. Fixed tissues were later embedded in paraffin, sectioned and stained with hematoxylin-eosin using standard protocols. For immunostaining, antigen retrieval containing 2.5 mg/mL BSA and 1mg/mL glucose, and centrifuged at 800 x g for 8 minutes and finally re-suspended in the same buffer. All centrifugation steps were done at room temperature and without brakes. with measurements collected at one-minute intervals. Raw fluorescence data was analyzed using Technothrombin TGA evaluation software.
Statistical analysis
The χ2 goodness-of-fit (GOF) test was used to determine deviation from expected Mendelian proportions. The χ2 test of independence was used for comparing two separate treatment groups. Exact binomial 95% confidence intervals (CI) were computed where appropriate. The Student's t test (2 tailed with unequal variance) was used for comparing embryo and placental sizes between groups and for comparing fluorescence values in thrombin generation assays. For all experiments, P < 0.05 was considered significant. 
